News
BMS signs $15.2bn R&D alliance with China's Hengrui
Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.
News
Partner's Bizengri is first drug for rare, aggressive cancer
Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.
Oncology
Dose optimisation in oncology: Insights from AACR 2026 and i...
Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026.
News
Manufacturing hangover drives Daiichi Sankyo into the red
Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.
News
CellCentric pockets $220m for blood cancer programme
CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
